# EDGAR Filing Document

**Accession Number:** 0002050902
**File Stem:** 0001193125-25-256980
**Filing Date:** 2025-10
**Character Count:** 13759
**Document Hash:** 05ffceaa41979273dfd5ea26fc18dc24
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-256980.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001193125-25-256980

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPT Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001673772
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473313701
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91191
- **FILM NUMBER:** 251431686

**BUSINESS ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 489-9000

**MAIL ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLX Bio, Inc.
- **DATE OF NAME CHANGE:** 20160504
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ForGrowth III PA B.V.
- **CENTRAL INDEX KEY:** 0002050902

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** FORBION CAPITAL PARTNERS
- **STREET 2:** GOOIMEER 2-35
- **CITY:** NAARDEN
- **STATE:** P7
- **ZIP:** 1411
- **BUSINESS PHONE:** 31 356993000

**MAIL ADDRESS:**
- **STREET 1:** FORBION CAPITAL PARTNERS
- **STREET 2:** GOOIMEER 2-35
- **CITY:** NAARDEN
- **STATE:** P7
- **ZIP:** 1411

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** RAPT Therapeutics, Inc.

**Title of Class of Securities:** Common Stock $0.0001 par value per share

**CUSIP Number:** 75382E208

**Date of Event Which Requires Filing of this Statement:** 10/23/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>ForGrowth III PA B.V. | Names of Reporting Persons<br>ForGrowth III PA B.V. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1833333 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1833333 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1833333 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1833333 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.4% | Percent of Class Represented by Amount in Row (9)<br>7.4% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Based on 24,869,403 shares of Common Stock outstanding following the closing of the offering as disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on October 22, 2025 (assuming no exercise of the over-allotment option described therein).

---

| 1. | Names of Reporting Persons<br>Forbion Growth Opportunities Fund III Cooperatief U.A. | Names of Reporting Persons<br>Forbion Growth Opportunities Fund III Cooperatief U.A. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1833333 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1833333 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1833333 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1833333 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.4% | Percent of Class Represented by Amount in Row (9)<br>7.4% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Based on 24,869,403 shares of Common Stock outstanding following the closing of the offering as disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on October 22, 2025 (assuming no exercise of the over-allotment option described therein).

---

| 1. | Names of Reporting Persons<br>Forbion Growth III Management B.V. | Names of Reporting Persons<br>Forbion Growth III Management B.V. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1833333 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1833333 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1833333 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1833333 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.4% | Percent of Class Represented by Amount in Row (9)<br>7.4% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Based on 24,869,403 shares of Common Stock outstanding following the closing of the offering as disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on October 22, 2025 (assuming no exercise of the over-allotment option described therein).

---

**Item 1(a). Name of Issuer:**
RAPT Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
561 Eccles Avenue, South San Francisco, CA 94080

**Item 2(a). Name of Person Filing:**
This statement is being filed by ForGrowth III PA B.V. ("ForGrowth III"), Forbion Growth Opportunities Fund III Cooperatief U.A. ("Forbion Growth III COOP") and Forbion Growth III Management B.V. ("Forbion Growth III"). ForGrowth III, Forbion Growth III COOP and Forbion Growth III are sometimes referred to collectively as the "Reporting Persons".

**Item 2(b). Address of Principal Business Office:**
The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.

**Item 2(c). Citizenship:**
Each of the Reporting Persons is organized under the laws of the Netherlands.

**Item 2(d). Title of Class of Securities:**
Common Stock $0.0001 par value per share

**Item 2(e). CUSIP Number:**
75382E208

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

ForGrowth III directly owns 1,833,333 shares of Common Stock. Forbion Growth III COOP, the sole shareholder of ForGrowth III, and Forbion Growth III, as director of each of ForGrowth III and Forbion Growth III COOP, may be deemed to have voting and investment power over the shares held directly by ForGrowth III.

**(b) Percent of class:**

The shares of Common Stock beneficially owned by the Reporting Persons represent approximately 7.4% of the outstanding shares of Common Stock of the Issuer, based on 24,869,403 shares of Common Stock outstanding following the closing of the offering as disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on October 22, 2025 (assuming no exercise of the over-allotment option described therein).

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

1,833,333

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

1,833,333

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

The Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a "group" for purposes of Rule 13d-5 or for any other purpose.

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**ForGrowth III PA B.V.**

**Date:** 10/29/2025

**By:** /s/ V. van Houten and /s/ G.J. Mulder

**Name & Title:** V. van Houten and G.J. Mulder, Directors of its Director

**Forbion Growth Opportunities Fund III Cooperatief U.A.**

**Date:** 10/29/2025

**By:** /s/ V. van Houten and /s/ G.J. Mulder

**Name & Title:** V. van Houten and G.J. Mulder, Directors of its Director

**Forbion Growth III Management B.V.**

**Date:** 10/29/2025

**By:** /s/ V. van Houten and /s/ G.J. Mulder

**Name & Title:** V. van Houten and G.J. Mulder, Directors